Streamline Bio offers an autonomous, cost-effective, AI-driven robotic platform designed for end-to-end cell and gene therapy (CGT) production – easy to use, smarter and built to grow with you.
Our platform automates key production steps using modular systems that evolve with your needs — empowering therapy developers to scale smarter, reduce manual touchpoints, and stay focused on what matters: delivering therapies to patients.
Autonomous, AI-driven systems engineered for the complexities of CGT production—delivering repeatable precision, reduced manual touchpoints, and seamless, end-to-end automation.
Our modular, plug-and-play architecture scales alongside your pipeline—adapting to new therapies and workflows without the need to overhaul your existing infrastructure.
Our solution adapts to your unique therapeutic workflows, helping you transition from early development to full-scale production.
We believe in growing together. In these early stages, we collaborate closely with CGT developers—offering flexible engagement models and deep technical support to co-create scalable solutions. Our goal is to be more than a vendor—we’re your long-term partner in bringing transformative therapies to patients for your manufacturing process.
Reduction in manual steps, minimizing error risk and easing compliance.
Improving consistency across production runs, enabling standardization, high-fidelity manufacturing.
Faster scale-up timelines.
Designed for a range of advanced therapies.